Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) has been assigned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $24.90.
A number of equities analysts have issued reports on the company. William Blair reiterated a “market perform” rating on shares of Fortrea in a research note on Wednesday, September 11th. Robert W. Baird dropped their target price on shares of Fortrea from $38.00 to $28.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Bank of America dropped their target price on shares of Fortrea from $26.00 to $21.00 and set an “underperform” rating on the stock in a research report on Tuesday, August 13th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Fortrea from $28.00 to $23.00 and set a “hold” rating on the stock in a research report on Tuesday, August 20th. Finally, Jefferies Financial Group cut shares of Fortrea from a “buy” rating to a “hold” rating and dropped their target price for the stock from $25.00 to $21.00 in a research report on Wednesday, September 25th.
View Our Latest Stock Analysis on FTRE
Institutional Investors Weigh In On Fortrea
Fortrea Stock Performance
Shares of FTRE opened at $18.79 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a 50-day moving average of $22.46 and a 200-day moving average of $27.69. The company has a market cap of $1.68 billion, a PE ratio of -13.52, a P/E/G ratio of 2.21 and a beta of 0.54. Fortrea has a one year low of $18.07 and a one year high of $41.02.
Fortrea (NASDAQ:FTRE – Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.10). The firm had revenue of $662.40 million during the quarter, compared to analyst estimates of $689.08 million. Fortrea had a negative net margin of 10.09% and a positive return on equity of 1.98%. The business’s quarterly revenue was down 8.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.52 earnings per share. On average, equities research analysts predict that Fortrea will post 0.6 EPS for the current fiscal year.
Fortrea Company Profile
Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Recommended Stories
- Five stocks we like better than Fortrea
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MarketBeat Week in Review – 9/30 – 10/4
- What is a Secondary Public Offering? What Investors Need to Know
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.